Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
<h4>Background and purpose</h4>Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic effects besides thrombolysis. We performed a meta-analysis to clarify effect of tissue plasminogen activator...
Saved in:
| Main Authors: | Mei-Xue Dong, Qing-Chuan Hu, Peng Shen, Jun-Xi Pan, You-Dong Wei, Yi-Yun Liu, Yi-Fei Ren, Zi-Hong Liang, Hai-Yang Wang, Li-Bo Zhao, Peng Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0158848 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparing effectiveness of tissue and plasma plasminogen activator thrombolysis in patients with various severity of acute myocardial infarction
by: V. A. Shulman, et al.
Published: (2005-12-01) -
Intravenous thrombolysis prevents neurological deterioration in patients with acute pontine infarction
by: Zhenxiao Chai, et al.
Published: (2025-01-01) -
Intravenous Thrombolysis Combined with Arterial Thrombolysis (Bridging Therapy) Effectively Improves Vascular Recanalization Rate in Patients with Cerebral Infarction
by: Junting Huo, et al.
Published: (2022-01-01) -
Carotid plaques and neurological impairment in patients with acute cerebral infarction.
by: Tongtian Ni, et al.
Published: (2020-01-01) -
Does the side of middle cerebral artery compromise matters in the mortality after thrombolysis in ischemic stroke?
by: Renata Dal-Prá Ducci, et al.
Published: (2015-08-01)